MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Total Assets 2011-2026 | PCRX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.55 B | 1.57 B | 1.68 B | 2.08 B | 1.27 B | 831 M | 689 M | 628 M | 391 M | 390 M | 326 M | 170 M | 112 M | 113 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 B | 112 M | 844 M |
Quarterly Total Assets Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 1.54 B | 1.59 B | 1.55 B | 1.52 B | 1.65 B | 1.58 B | 1.57 B | 1.53 B | 1.54 B | 1.52 B | 1.68 B | 1.73 B | - | 1.89 B | 2.08 B | 1.36 B | 1.33 B | 1.29 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B | 831 M | 831 M | 831 M | 831 M | 689 M | 689 M | 689 M | 689 M | 628 M | 628 M | 628 M | 628 M | 391 M | 391 M | 391 M | 391 M | 388 M | 388 M | 388 M | 388 M | 326 M | 326 M | 326 M | 326 M | 170 M | 170 M | 170 M | 170 M | 112 M | 112 M | 112 M | 112 M | 113 M | 113 M | 113 M | 113 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 B | 112 M | 827 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 0.95 | -2.04 % | $ 102 M |  Canada |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.29 | -0.61 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.93 B | $ 2.51 | -0.31 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 7.96 | -1.12 % | $ 408 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.15 | 3.28 % | $ 44.3 M | USA |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 1.05 | 2.45 % | $ 24.5 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 4.98 | -2.35 % | $ 1.82 B | Canada |
 |
Solid Biosciences
SLDB
|
233 M | $ 6.9 | -3.36 % | $ 604 M | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.39 | -6.13 % | $ 2.97 M | USA |
 |
Harrow Health
HROW
|
399 M | $ 35.27 | 3.74 % | $ 1.3 B | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
4.31 B | $ 6.43 | -0.31 % | $ 3.97 B | Canada |
 |
Evolus
EOLS
|
226 M | $ 4.61 | -1.6 % | $ 297 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.3 | - | $ 310 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 6.06 | 3.41 % | $ 239 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.88 | 0.79 % | $ 43.9 M | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.35 | 1.73 % | $ 24.5 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.78 | 2.25 % | $ 3.36 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.42 | -2.23 % | $ 319 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 9.64 | 0.68 % | $ 1.34 B | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 15.21 | 8.64 % | $ 97.4 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |